Semax vs Selank at Deep Dive Peptides
A comparison by tissue, test and outcome, with room for the alternative searches that the available sources cannot settle.
Semax and Selank side by side
I can make a useful comparison of where these compounds were tested. Ranking them for a healthy person’s focus would require a different set of studies. The most revealing overlap in this source list is a shared assay of enzymes from human serum: both peptides slowed the breakdown of enkephalins outside the body.
That common finding coexists with different structures and research aims. Semax starts from an ACTH fragment; Selank starts from tuftsin. Each has an added Pro-Gly-Pro tail. A shared tail or assay result leaves plenty of room for different biological effects.
Brain regions and measurements
| Location or test | Semax | Selank |
|---|---|---|
| Rat hippocampus | NGF and BDNF messenger RNA increased | BDNF expression increased |
| Rat frontal cortex | NGF messenger RNA decreased | GABA-related gene expression changed |
| Rat basal forebrain | BDNF protein increased at 3 hours | No matched measurement in this source list |
| Human serum, outside the body | Enkephalin-degrading enzymes inhibited | Same assay found inhibition |
The entries occupy different experiments. This is a comparison of observations, with no common scale for declaring one compound stronger. For comparison, I’d take those tissue names over the broad category “brain support.”
Behavior after injury or stress
The Semax cortical injury study in rats measured retained memory of a learned danger and cortical infarct volume. The Selank stress study in rats measured anxiety-like behavior, with the strongest result from Selank plus diazepam. Memory after injury and anxiety after stress are different outcomes.
The 2025 Semax spinal injury experiment involved female mice and locomotor recovery. Its inclusion adds another useful observation, while making an overall performance ranking still less coherent. I’d rather compare the function being tested before comparing the compounds.
Semax alternative, Adamax and Dihexa
Searches for a “Semax alternative,” “Selank vs Semax vs Adamax” or “Semax vs Dihexa” ask a reasonable practical question: could a different compound do the same job? This site’s audited sources cover Semax and Selank. They contain no head-to-head trial that settles those Adamax or Dihexa comparisons.
I have no evidential basis here for a substitute recommendation or an ordering by strength. Even between Semax and Selank, overlap in BDNF-related rodent findings gives a reason for a mechanistic question rather than an interchangeable human treatment. The references make the boundary of that comparison explicit.
Selank amidate and amount labels
The “Selank 10 mg amidate” query needs an identity check before any comparison of effects. An amount beside a name gives no information about the study population, the measured outcome or whether a modified molecule was tested. These papers cannot validate a commercial label or establish equivalence between an amidate variant and the Selank used in the cited research.
The amount is reproduced here only as part of the search phrase. It carries no recommendation for a person. I’d need evidence specific to the modified compound before transferring a finding across.
Human evidence and combinations
The Selank immune study involved patients with anxiety and exhaustion and measured immune signaling. Most detailed Semax findings in this list concern animals or tissue. Neither collection answers the whole set of human questions about lasting memory, anxiety relief and harm.
Published human work comes mainly from a small set of Russian groups, often with limited English methodological detail. I’d put replication by other groups and longer follow-up ahead of another mechanistic explanation, especially where a claimed benefit depends on repeated exposure.
Interaction uncertainty is particularly important: Selank plus diazepam changed anxious behavior in rats, and both peptides affected enkephalin-degrading enzymes in vitro. These findings justify questions about combinations with other medicines, while human combination safety remains unsettled.
Medicine rules differ between countries
Neither Semax nor Selank is approved by the FDA or EMA for any indication. Both hold prescription-drug status in Russia (Semax for ischemic stroke, TIA and cognitive impairment; Selank as an anxiolytic for anxiety-asthenic disorders), but this registration does not confer approved status in Western countries. Both compounds remain on sale in the United States as research-labelled lab material; that route coexists with prescription care for compounded medication, assessed one patient at a time. On WADA's Prohibited List, Semax is not named explicitly but may fall under the S0 non-approved substances catch-all; Selank is not specifically listed but the same S0 reasoning could apply. Athletes under anti-doping rules should check GlobalDRO and consult the relevant authority before any use.
For the blended Semax/Selank medication, Promise Peptides has begun prescribing; mypromise.com describes this prescription care. A clinician licensed in the U.S. studies each request before choosing whether to prescribe. An assessment can end without a prescription. This service takes U.S. patients only, with care choices shaped by the state and treatment under discussion. Its compounded Semax/Selank medicine has no FDA approval.
Choosing the next paper
The regional table helps me test an attractive general claim against the actual location of a finding. Hippocampus, frontal cortex, serum and spinal cord point to different biological questions.
For a closer look at the molecular observations, there are the Semax regional findings and Selank mechanisms. For identity, safety and registration questions, the FAQ gathers the distinctions. Personal treatment choices need a clinician’s assessment of the actual health problem.